84 Lenaldomde was dosed at 25 mg day odays 1 21 each 28 days.Patents thehgh dose arm receved dexamethasone 40 mg day odays 1 four, 9 twelve, and 17 20 every 28 days, whereas patents the reduced dose arm receved dexamethasone forty mg day odays 1, 8, 15, and 22 each 28 days.Wththe frst 4 cycles of treatment, a response of PR orhgher was see82% of patents handled wth lenaldomde plushgh dose dexamethasone versus 70% of patents discover this the lenaldomde plus lower dose dexamethasone arm.CR plus VGPR prices were 52% versus 42%, respectvely.a phase review, 34 prevously untreated MM patents have been admnstered lenaldomde 25 mg day odays one 21 of the 28 day cycle and dexamethasone forty mg day odays one four, 9 12, and 17 twenty of every cycle for not less than 4 cycles.42 Treatment method wth lenaldomde plus dexamethasoneelded aTTof 91%, ncludng sx patents wth a CR and 13 who met the crtera for VGPR and nCR.
42,43 Between 21 patents who dd not subsequently receve SCT and were elgble for treatment method beyond four cycles at the dscretoof the nvestgator, 14 acheved ether a CR or VGPR.43 Lenaldomde cyclophosphamde dexamethasone additional hints A phase review of 33 patents wth newly dagnosed MM evaluated the combnatoof lenaldomde 25 mg day odays 1 28 of every 28 day cycle, cyclophosphamde 300 mg m2 odays one, 8, and 15 of each cycle, and dexamethasone forty mg day odays one, eight, 15, and 22 of each cycle.85 Between 19 of 33 evaluable patents, two acheved a VGPR and 13 acheved a PR, gvng aORR of 78.9%.Lenaldomde bortezomb dexamethasone a phase research, the combnatoof lenaldomde 15 25 mg day odays one 14, bortezomb one.0 one.
3 mg m2 odays one, four, eight, and 11, and dexamethasone forty twenty mg day oday of and day immediately after bortezomb admnstratofor uto eght 21 day cycles produced aORR of 98% 42 evaluable patents wth newly dagnosed MM.86 Nne of 42 patentshad a CR, 3had nCR, 10had VGPR, and 19had PR, gvng aORR of 98% at the tme of ths

analyss.All eleven patents who receved therapy wth lenaldomde bortezomb dexamethasone RVd on the phase dose level of lenaldomde 25 mg, bortezomb one.three mg, and dexamethasone 20 mg acheved PR or greater.Clarthromyclenaldomde dexamethasone a phase examine of 72 patents wth newly dagnosed MM, nductotherapy wth clarthromyc500 mg twce day, lenaldomde 25 mg day odays one 21 of the 28 day cycle, and dexamethasone forty mg day as soon as weekly was assocated wth aobjectve response of PR or superior 65 patents, ncludng a CR rate of 38.9%.87 Ffty three patents acheved no less than a 90% lower M protelevels.The meaduratoof response was 333 days as well as the meatme to response was 54 days, wth a meatme to maxmum response of 209 days.Patents wth atypcal serum mmunofxatopatterdevelopment durng nductotherapy wth BRDhad sgnfcantly better response thapatents wthout ASP, wth a CR rate of 71% versus 23%, respectvely.